Flagyl is a longstanding U.S. brand name for metronidazole, a prescription nitroimidazole medicine. A brand search can be misleading because the historic Flagyl 250 mg and 500 mg tablets, the 375 mg capsule presentation, and today's generic oral metronidazole listings are not one uniformly marketed product. The useful starting point is to read the prescription's formulation and strength, not to assume that every Flagyl result describes the same item. For an overview of current oral product families, see the oral metronidazole product guide.
The FDA lists the original Flagyl 250 mg and 500 mg branded tablets in its discontinued drug product list. That designation should not be mistaken for a conclusion that metronidazole itself is no longer prescribed: approved generic oral tablets remain a separate product category. In a 2024 determination, FDA said the branded tablet withdrawal was not for safety or effectiveness reasons. The 375 mg Flagyl capsule has distinct U.S. labeling; it should not be described as an ordinary 375 mg tablet or presumed available at any particular seller.
This page explains the Flagyl brand entity, its U.S. labeling history, capsule identity and relationship to generics. If you already have a valid prescription and need lawful dispensing steps, use the oral metronidazole pharmacy guide. Specific strengths, prices, insurance benefits, antibiotic choices and current pharmacy inventory require separate verification rather than generalized brand claims.
Flagyl is a proprietary name attached to metronidazole oral products. It does not identify a vaginal formulation of the same medicine or the dermatologic cream and gel products used for rosacea. FDA-approved product identity is tracked at the application, dosage form, route and strength level. An old package photo, search snippet or drug dictionary entry may still show a brand after a particular presentation has stopped being marketed.
The practical distinction is between the branded Flagyl tablet family in the historical record, the 375 mg Flagyl capsule and the separate generic tablet or capsule products a pharmacist may evaluate against a prescription. For a brand-to-generic comparison, see Flagyl versus generic metronidazole; this brand page concentrates on the meaning of Flagyl itself.
| U.S. product identity | What the record indicates | What a reader should verify |
|---|---|---|
| Flagyl tablets 250 mg | Branded tablet presentations listed as discontinued | Do not assume that an advertised Flagyl tablet is a current branded U.S. package |
| Flagyl tablets 500 mg | Same historical branded tablet status, with generic products considered separately | Check whether the prescription permits an appropriately approved generic |
| Flagyl 375 mg capsules | Distinct prescription capsule labeling and product identity | Verify capsule dosage form, branded listing and dispensing possibility |
| Generic metronidazole tablets | Separate approved generic products may have current listings | Match strength, manufacturer, route and valid prescription |
A medicine can be marked discontinued in the FDA Orange Book even when the active ingredient is still used and other manufacturers continue to market approved formulations. Discontinued product status is not a universal warning against the molecule, an automatic recall, or proof that all related generics disappeared. For the original 250 mg and 500 mg Flagyl tablets, FDA explicitly determined that withdrawal was not for safety or effectiveness reasons.
That regulatory distinction matters for search results headed 'buy Flagyl 500.' A historical label or product database page does not demonstrate that an authentic current U.S. branded tablet can be dispensed. A prescriber may write metronidazole generically or specify a brand; the pharmacist must apply the actual order and substitution requirements. The generic metronidazole guide details the broader generic product landscape without presenting discontinued brands as in-stock offers.
The 375 mg Flagyl capsule is not a renamed 250 mg or 500 mg tablet. It has its own formulation, product labeling, packaging history and prescription considerations. The label describes a 375 mg oral capsule and includes drug-specific precautions. Even when a study in labeling discusses equivalent metronidazole exposure at an equal total administered amount, that does not authorize a patient to construct a substitute dose from different strengths or forms.
When a prescription specifically names a capsule, confirm that the dispensing pharmacist is interpreting that dosage form, rather than assuming 'metronidazole' means an immediate-release tablet. Read the dedicated 375 mg capsule guide for product identification and comparison with approved capsule listings. If an item cannot be sourced, any proposed change belongs with the prescriber and pharmacist.
FDA-approved generics are assessed against specific reference drugs and product requirements. Generic equivalence cannot be inferred from one shared active ingredient alone: route, dosage form, strength, and where applicable release characteristics all matter. A generic 500 mg oral tablet, an extended-release 750 mg tablet, and a 375 mg capsule all contain metronidazole but represent different prescriptions and may have different directions.
State pharmacy rules and the written prescription affect whether a pharmacist may substitute one manufacturer or product for another. There is no sound reason to pay extra for an unverified 'imported Flagyl' listing merely because the historic name is recognizable. The appropriate question is whether the pharmacist can dispense a legitimate U.S. product that satisfies the prescribed order or has obtained prescriber authorization for a change.
Systemic oral metronidazole is used under professional supervision for certain susceptible anaerobic bacterial and protozoal infections; prescribing depends on diagnosis, patient history and the relevant product label. A search for Flagyl alone cannot tell a clinician which infection is present. The same symptoms may reflect different conditions, and using an antimicrobial without appropriate evaluation can delay diagnosis or contribute to resistance.
Metronidazole is also used in distinct formulations for bacterial vaginosis and rosacea, but those products have separate routes and labeled uses. Someone researching BV should not assume that a vaginal gel is appropriate for a condition requiring oral therapy, or vice versa. If the underlying question is whether an antibiotic is indicated at all, clinical assessment matters more than the presence of a familiar brand name.
The FDA Orange Book helps distinguish approved products and their application records, including marketing status classifications and some therapeutic-equivalence evaluations. DailyMed provides current and archived structured labeling submitted for listed drug products. Neither is a live inventory service. The same brand may have multiple packages or older labels with different revision dates, which is why checking only the first result is unreliable.
Match the exact proprietary name, active ingredient, tablet or capsule, strength, application status and labeling date. If an online pharmacy listing uses an unfamiliar package, check the U.S. product identifier and the pharmacy's license rather than treating a search-result thumbnail as authentication. The product availability checklist explains why regulatory records and a pharmacy's actual supplier inventory answer different questions.
First, a licensed clinician determines whether oral metronidazole is appropriate. Next, the prescription specifies the intended formulation, strength, directions and quantity. Only then does a licensed pharmacy decide whether it can legally dispense the exact product or a permitted equivalent. Buying a name from a third-party marketplace without the required clinical and dispensing safeguards reverses the proper process.
A U.S. online pharmacy should require a valid prescription, identify a real U.S. address and provide access to a licensed pharmacist. A local pharmacy can likewise check the order and explain any brand-to-generic proposal. For buying logistics, use the online pharmacy verification guide rather than relying on seller claims about historic Flagyl stock.
Flagyl's long market history does not make it an over-the-counter antibiotic or a medicine appropriate for self-treatment. Oral metronidazole labeling includes important warnings, including a boxed warning about carcinogenicity findings in rodents and precautions relating to neurologic symptoms, interactions and adverse reactions. A prescriber must interpret these issues in light of the patient and the condition being treated.
Tell the treating clinician and pharmacist about other medicines and relevant medical history. Do not use leftover capsules, combine different metronidazole strengths, or take a historic dosing schedule found in a search result as personalized instructions. Severe or unexpected symptoms warrant professional medical advice; potential emergencies warrant urgent care.
Comparing a discontinued branded Flagyl tablet with a generic metronidazole tablet is not a meaningful live-price comparison. Published cash offers can involve different product codes, strengths and quantities, and some entries refer to old or unfillable brand names. A pharmacist can explain whether a brand request is actionable or whether the prescription supports a generic product.
For a stable framework, review oral metronidazole cost factors and compare like-for-like quotes only after the actual product has been identified. Insurance formularies, deductibles, dispensing fees and pharmacy networks may change the final patient cost. This page does not publish figures or endorse unverified sellers.
Ask whether the clinician intended branded Flagyl or metronidazole generically, whether the order is for tablets or 375 mg capsules, and whether the prescribed strength and quantity match a legally dispensable product. A pharmacist should resolve an ambiguous historic brand reference before the prescription is filled; the patient should not translate between capsule and tablet counts independently.
Also ask whether the medicine on offer is U.S.-approved for the ordered route, whether a substitution requires prescriber contact, and whether insurance terms apply to the precise product. These are more durable checks than claims of 'Flagyl back in stock' or price listings that lack date, formulation and manufacturer details.
Flagyl is a U.S. brand name associated with oral metronidazole, a prescription nitroimidazole antimicrobial. The brand name alone does not identify every available formulation or route.
FDA lists the original branded 250 mg and 500 mg tablet products as discontinued. That does not mean generic metronidazole tablets are no longer available, nor does it establish any pharmacy inventory.
In a 2024 determination, FDA concluded the discontinued 250 mg and 500 mg branded tablets were not withdrawn for safety or effectiveness reasons. This is distinct from the medicine’s important labeled warnings.
Flagyl 375 is a branded oral metronidazole capsule presentation with its own labeling. It is not the same dosage form as a 250 mg or 500 mg tablet.
An appropriately approved generic may be dispensable when it matches the prescription and applicable substitution rules. The pharmacist must evaluate the precise strength, form and order.
No. The oral metronidazole products discussed here require a valid prescription and lawful dispensing.
No. A published drug label is a reference record, not evidence of present-day local or online stock.
No. The products have different routes, formulations and treatment uses. They cannot be exchanged simply because both contain metronidazole.
Do not alter strength, dosage form or directions on your own. Ask the pharmacist to contact the prescriber if the exact product cannot be dispensed.
First establish which product and strength will actually be dispensed. Then check the same formulation and quantity at eligible licensed pharmacies and verify insurance terms.